Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic
"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

VALEANT PHARMACEUTICALS INTL INC > Valeant new psoriasis drug will make $1 billion in 2018
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by deeppocket83on May 04, 2017 11:19am
111 Views
Post# 26203152

RE:RE:Valeant new psoriasis drug will make $1 billion in 2018

RE:RE:Valeant new psoriasis drug will make $1 billion in 2018I think it will be more around 500M to 1B. VRX will hit 30 by end of year. Joe did you go long yet or still mopping around preaching going to zero?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities